Gel for treating skin diseases such as dermatitis and eczema and preparation method and application of gel for treating skin diseases such as dermatitis and eczema

A gel and skin disease technology, applied in the field of gel and preparation for the treatment of dermatitis and eczema skin diseases, can solve the problems of complex etiology and pathogenesis, easy repetition, long treatment cycle, etc., and achieve good spreadability and easy application Soft and delicate, good anti-itching effect

Inactive Publication Date: 2016-11-23
ARMY MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, glucocorticoids, H1 receptor antagonists, and some non-steroidal anti-inflammatory drugs are mainly used for systemic or local drug treatment in clinical practice. Repeatedly, in addition to the potential side effects of long-term use of the above-mentioned drugs, it has become an urgent clinical need to develop anti-dermatitis eczema drugs with positive curative effect and less toxic side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gel for treating skin diseases such as dermatitis and eczema and preparation method and application of gel for treating skin diseases such as dermatitis and eczema
  • Gel for treating skin diseases such as dermatitis and eczema and preparation method and application of gel for treating skin diseases such as dermatitis and eczema
  • Gel for treating skin diseases such as dermatitis and eczema and preparation method and application of gel for treating skin diseases such as dermatitis and eczema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 10

[0037] Example 10 Single TPA (phorbol ester)-induced mouse ear swelling inhibition experiment

[0038] The anti-inflammatory activity of each group of gels in Examples 1, 2, 3, 4, 5, 6, 7, 8, and 9 was tested by inhibiting mouse ear swelling induced by a single TPA.

[0039] experiment method:

[0040] During the test, 40 mg of the substance in the embodiment is applied to the inside and outside of the right auricle of male Kunming mice with a body weight of 26-30 g, and the negative group is smeared with a blank matrix (not containing THCA354 compound), and after 20 min, TPA (0.1 μg / μL, acetone solvent) 20μL causes inflammation. Before administration and after giving TPA 6h, measure the ear thickness of each group of mice with a thickness gauge, calculate the degree of swelling, and ask for the average value. Compared with the negative control group, the results are shown in figure 1 .

[0041] Calculate inhibition rate. The experimental results are listed in Table 2:

...

Embodiment 11

[0046] Example 11 Inhibitory Experiment of Arachidonic Acid-Induced Mouse Ear Swelling

[0047] The anti-inflammatory activity of the gels of Examples 1, 2, 3, 4, 5, 6, 7, 8, and 9 was tested by inhibiting arachidonic acid-induced mouse ear swelling.

[0048] experiment method:

[0049] During the test, 40 mg of the substance in the embodiment was applied to the inside and outside of the right auricle of male Kunming mice with a body weight of 26-30 g, and the negative group was smeared with a blank matrix (not containing THCA354 compound), and after 15 minutes, it was treated with arachidonic acid (0.2mg / μL) 20μL causes inflammation. Before administration and after giving TPA 1h, measure the ear thickness of each group of mice with a thickness gauge, calculate the degree of swelling, and calculate the average value. Compared with the negative control group, the results are shown in figure 2 .

[0050] Calculate the inhibition rate, and the experimental results are listed ...

Embodiment 12

[0054] Example 12 DNFB-induced mouse delayed-type hypersensitivity inhibition experiment

[0055] experiment method:

[0056] During the experiment, female BABL / c mice weighing 16-18 g were randomly divided into model group, positive control group, dexamethasone acetate group, ethoxysamide ointment group, Example 9 group, and healthy group.

[0057] After abdominal hair clipping, mice were depilated with depilatory cream, and after one day of adaptive feeding, 0.5% DNFB was given to stimulate 75uL / mouse (solvent: acetone: olive oil=4; 1) at the abdominal depilated place. Apply 0.5% DNFB to the ear for secondary stimulation, and the dosage is 20ul / ear. 6 hours after the stimulation, measure the degree of mouse ear swelling to observe the onset of the model. On the sixth day, the right ear of the mouse was re-applied and given 0.4% DNFB for three stimulations. The thickness of the mouse ear tissue was measured 6 hours and 24 hours after the stimulation to evaluate whether the m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a gel for treating eczema-like skin diseases, its preparation method and application. The gel comprises a raw material drug THCA354, a forming agent, a synergist, a bacteriostatic agent, a moisturizing agent, a dispersing agent and water. The gel preparation has anti-inflammation, anti-allergic and anti-itching effects, and has the characteristics of high local therapeutic concentration, rapid action, and small systemic side effects.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a gel for treating dermatitis and eczema skin diseases, a preparation method and application. Background technique [0002] Dermatitis eczematous skin disease is a common delayed-type allergic skin disease that occurs in the superficial layer of the skin and has a tendency of redness, swelling and exudation. It is often accompanied by pathological characteristics and clinical manifestations such as skin infiltration, hypertrophy, and severe itching. [0003] In recent years, with the increasing environmental pollution and the change of human life and work style, the incidence of the disease is increasing year by year. Currently, glucocorticoids, H1 receptor antagonists, and some non-steroidal anti-inflammatory drugs are mainly used for systemic or local drug treatment in clinical practice. Repeatedly, in addition to the potential side effects of the long-te...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K31/216A61K47/10A61P29/00A61P37/08A61P17/04A61P17/00
CPCA61K9/06A61K31/216A61K47/10
Inventor 张惠静汤建林刘欢韩清娟胡岚岚
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap